A Double-Blind, Randomized, Four-Period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 Years
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2015
At a glance
- Drugs Dapagliflozin; Moxifloxacin
- Indications Bacterial infections; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 05 Jun 2009 Results presented at ADA 2009.
- 23 Jun 2008 New trial record.